| 名稱(chēng) | TFG-NTRK1/BaF3 |
| 型號(hào) | CBP73193 |
| 報(bào)價(jià) |  |
| 特點(diǎn) | TFG-NTRK1/BaF3,母細(xì)胞：BaF3，凍存條件：90% FBS+10% DMSO； |
產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- ERBB2基因檢測(cè)標(biāo)準(zhǔn)品
- ATCC細(xì)胞冷凍保存方法
- 血液系統(tǒng)惡性腫瘤治療研究熱點(diǎn)
- MicroRNA或可特異性地殺死攜帶常見(jiàn)突變的癌細(xì)胞
- atcc細(xì)胞的細(xì)胞核分離原理說(shuō)明
- 探討腫瘤細(xì)胞的“冷與熱”之分
- 新品發(fā)布【地中海貧血標(biāo)準(zhǔn)品】
- Cell Rep：發(fā)現(xiàn)治療乳腺癌轉(zhuǎn)移的重要新靶標(biāo)！
- atcc細(xì)胞培養(yǎng)紫外燈照射的目的與實(shí)踐
- 分子診斷標(biāo)準(zhǔn)品，選擇科佰生物
聯(lián)系我們
聯(lián)系人：蔣經(jīng)理
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
電話：4008750250
號(hào)碼：
手機(jī)：18066071954
地址：南京市棲霞區(qū)緯地路9號(hào)
Email： zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73193TFG-NTRK1/BaF3
- 詳細(xì)內(nèi)容
CBP73193 | |
| I. Introduction | |
Cell Line Name： | TFG-NTRK1/BaF3 |
Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10% FBS+1 ug/ml puromycin |
Mycoplasma Status: | Negative |
| II.Background | |
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013). a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013). b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013). c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013) | |
| III. Representative Data | |
1. WB of TFG-NTRK1/BaF3 expression | |
| |
2. Anti-proliferation assay | |
| |
Figure 2. Anti-proliferation assay of two reference compounds on the TFG-NTRK1/BaF3 Stable Cell Line | |
會(huì)員_a.png)